VivoSeq
Neurology

Chronic Inflammatory Demyelinating Polyneuropathy

23

Pipeline Programs↗

11

Active Trials↗

13

Companies Involved↗

Chronic Inflammatory Demyelinating Polyneuropathy is an emerging landscape with 23 programs across 13 companies. The most active players are Gilead, Bioverativ, a Sanofi company, NovaMed Pharmaceuticals Inc.. 10 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

86/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 1B

Bioverativ, a Sanofi company

1 program

Phase 2N

NovaMed Pharmaceuticals Inc.

1 program

Phase 2D

Dianthus Therapeutics

2 programs

Phase 3Grifols Therapeutics LLC logo

Grifols Therapeutics LLC

1 program

Phase 3N

Nihon Pharmaceutical Co., Ltd

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

13 of 19 classified programs — the dominant modality here.

32%ALL OTHERSMonoclonal antibody526%Cell therapy15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 85% of 27 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed12 · 44%
Recruiting8 · 30%
Withdrawn2 · 7%
No longer available1 · 4%
Active, not recruiting1 · 4%
Available1 · 4%
Other2 · 7%

Clinical Trials

Trial Activity

27 trials

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Recruiting·UUniversity of Ulm·Phase 2·NCT04881682·20 enrolled
Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Recruiting·—·Phase 3·NCT06714838·100 enrolled
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Recruiting·Sanofi logoSanofi·Phase 3·NCT06290128·140 enrolled
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Recruiting·DDianthus Therapeutics·Phase 3·NCT06858579·256 enrolled
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
Recruiting·Sanofi logoSanofi·Phase 3·NCT06290141·160 enrolled
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT07032662·162 enrolled
A Double-blind, Randomized, Multi-Center Study Investigating Efficacy and Safety of Two Different Dosages of Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Recruiting·—·Phase 3·NCT06752356·161 enrolled
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases
Recruiting·Gilead logoGilead·Phase 1·NCT07304154·52 enrolled
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Active, not recruiting·Argenx logoArgenx·Phase 2·NCT04280718·229 enrolled
Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
Not yet recruiting·—·Phase 3·NCT06858722·175 enrolled
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Enrolling by invitation·IImmunovant Sciences GmbH·Phase 2·NCT07188844·108 enrolled
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Completed·CSL Behring logoCSL Behring·Phase 3·NCT01545076·208 enrolled
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Completed·NNorthwestern University·Phase 2·NCT00278629·80 enrolled
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004772·90 enrolled
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Completed·BBioverativ, a Sanofi company·Phase 2·NCT04658472·98 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)